Real-World Antipsychotic Treatment Practices

Psychiatric Clinics of North America

Volumn 30, Issue 3, 2007, Pages 401-416

  Moore, Troy A ^a   Covell, Nancy H ^b,c   Essock, Susan M ^d,e   Miller, Alexander L ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Research Division   (United States)

^d Columbia University ^*  (United States)

^e NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; HYPNOTIC SEDATIVE AGENT; LITHIUM; MOOD STABILIZER; OLANZAPINE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; SULPIRIDE; ZIPRASIDONE;

AGRANULOCYTOSIS; ALGORITHM; AUTHOR; CLINICAL TRIAL; COMPARATIVE STUDY; DECISION MAKING; DIABETES MELLITUS; DRUG SELECTIVITY; DRUG USE; DRUG WITHDRAWAL; EVALUATION; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERLIPIDEMIA; MEDICAL PRACTICE; POLYPHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; STRENGTH; TARDIVE DYSKINESIA; WEIGHT GAIN;

ALGORITHMS; ANTIPSYCHOTIC AGENTS; EVIDENCE-BASED MEDICINE; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; SCHIZOPHRENIA;

EID: 34548076539     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psc.2007.04.008     Document Type: Review

References (100)

1. Lieberman J.A., Stroup T.S., McEvoy J.P., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353 12 (2005) 1209-1223
2. Lehman AF, Lieberman JA, Dixon LB, et al. Work Group on Schizophrenia. American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. 2nd edition. 2004. Available at: http://www.psych.org/psych_pract/treatg/pg/Schizophrenia2ePG_05-15-06.pd f. Accessed October 13, 2006.
3. McIntyre JS, Charles SC, Anzia DJ, et al. American Psychiatric Association. Treating schizophrenia: a quick reference guide. Available at: http://www.psych.org/psych_pract/treatg/quick_ref_guide/Schizophrenia_QR G.pdf. Accessed October 13, 2006.
4. McEvoy J.P., Scheifler P.L., and Frances A. The Expert Consensus Guideline Series: treatment of schizophrenia 1999. J Clin Psychiatry 60 Suppl 11 (1999) 1-81
5. Miller A.L., Hall C.S., Buchanan R.W., et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry 65 (2004) 500-508
6. Lehman A.F., Kreyenbuhl J., Buchanan R.W., et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull 30 2 (2004) 193-217
7. The International Psychopharmacology Algorithm Project. IPAP schizophrenia algorithm. Available at: www.ipap.org/schiz. Accessed October 13, 2006.
8. Duggan M. Do new prescription drugs pay for themselves? The case of second-generation antipsychotics. J Health Econ 24 (2005) 1-31
9. IMS Health. Atypical antipsychotics: generating evidence to inform policy and practice. Available at: http://research.imshealth.com/research_schizophrenia.htm. Accessed December 18, 2006.
10. Lieberman J.A., Phillips M., Gu H., et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 28 5 (2003) 995-1003
11. Woerner M.G., Robinson D.G., Alvir J.M.J., et al. Clozapine as a first treatment of schizophrenia. Am J Psychiatry 160 8 (2003) 1514-1516
12. Emsley R.A. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Schizophr Bull 25 4 (1999) 721-729
13. Schooler N., Rabinowitz J., Davidson M., et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomised trial. Am J Psychiatry 162 (2005) 947-953
14. Robinson D.G., Woerner M.G., Napolitano B., et al. Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Am J Psychiatry 163 (2006) 2096-2102
15. McEvoy JP, Lieberman JA, Perkins D, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind, 52-week comparison. Am J Psychiatry, in press.
16. Lieberman J.A., Tollefson G., Tohen M., et al., HGDH Study Group. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 160 8 (2003) 1396-1404
17. Green A.I., Lieberman J.A., Hamer R.M., et al., HGDH Study Group. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res 86 (2006) 234-243
18. Lublin H., Eberhard J., and Levander S. Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. Int Clin Psychopharmacol 20 (2005) 183-198
19. Corell C.U., Leucht S., and Kane J.M. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 161 3 (2004) 414-425
20. Oosthuizen P.P., Emsley R.A., Maritz J.S., et al. Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. J Clin Psychiatry 64 (2003) 1075-1080
21. Buckley P., Miller A.L., Olsen J., et al. When symptoms persist: clozapine augmentation strategies. Schizophr Bull 27 (2001) 615-628
22. Claghorn J., Honigfeld G., Abuzzahab F.S., et al. The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 7 (1987) 377-384
23. Kane J.M., Honigfeld G., Singer J., et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45 (1988) 789-796
24. Pickar D., Owen R.R., Litman R.E., et al. Clinical and biological response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Arch Gen Psychiatry 49 (1992) 345-353
25. Breier A., Buchanan R.W., Kirkpatrick B., et al. Clozapine in schizophrenic outpatients: effects on positive and negative symptoms. Arch Gen Psychiatry 151 (1994) 20-26
26. Carpenter Jr. W.T., Conley R.R., Buchanan R.W., et al. Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry 152 (1995) 827-832
27. Essock S.M., Hargreaves W.A., Covell N.H., et al. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull 32 (1996) 683-697
28. Volavka J., Czobor P., Sheitman B., et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 159 (2002) 255-262 [erratum: 159: 2132]
29. Chakos M., Lieberman J., Hoffman E., et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 158 (2001) 518-526
30. Conley R.R., Kelly D.L., Richardson C.M., et al. The efficacy of high-dose olanzapine in treatment-resistant schizophrenia: a double-blind, crossover study. J Clin Psychopharmacol 23 6 (2003) 668-671
31. McEvoy J.P., Lieberman J.A., Stroup T.S., et al. Effectivness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163 (2006) 600-610
32. Ereshefsky L. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. J Clin Psychiatry 60 Suppl 10 (1999) 20-30
33. Fourrier A., Gasquet I., Allicar M.P., et al. Patterns of neuroleptic drug prescription: a national cross-sectional survey of a random sample of French psychiatrists. Br J Clin Pharmacol 49 1 (2000) 80-86
34. Ito C., Kubota Y., and Sato M. A prospective survey on drug choice for prescriptions for admitted patients with schizophrenia. Psychiatry Clin Neurosci 53 Suppl (1999) S35-S40
35. Keks N.A., Altson K., Hope J., et al. Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service. Aust N Z J Psychiatry 33 6 (1999) 896-901
36. Meltzer H.Y., and Kostaoglu A.E. Combining antipsychotics: is there evidence for efficacy?. Psychiatric Times 17 9 (2000) 25-34
37. Rittmannsberger H., Meise U., Schauflinger K., et al. Polypharmacy in psychiatric treatment. Patterns of psychotropic drug use in Austrian psychiatric clinics. Eur Psychiatry 14 1 (1999) 33-40
38. Stahl S.M. Antipsychotic polypharmacy, part 2: tips on use and misuse. J Clin Psychiatry 60 8 (1999) 506-507
39. Stahl S.M. Antipsychotic polypharmacy, part 1: therapeutic option or dirty little secret?. J Clin Psychiatry 60 7 (1999) 425-426
40. Tapp A., Wood A.E., Secrest L., et al. Combination antipsychotic therapy in clinical practice. Psychiatr Serv 54 1 (2003) 55-59
41. Centorrino F., Fogarty K.V., Sani G., et al. Use of combinations of antipsychotics: McLean Hospital inpatients, 2002. Hum Psychopharmacol 20 (2005) 482-492
42. Ganguly R., Kotzan J.A., Miller L.S., et al. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry 65 (2004) 1377-1388
43. Ito H., Koyama A., and Higuchi T. Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription. Br J Psychiatry 187 (2005) 243-247
44. Biancosino B., Barbui C., Marmai L., et al. Determinants of antipsychotic polypharmacy in psychiatric inpatients: a prospective study. Int Clin Psychopharmacol 20 (2005) 305-309
45. Brunot A., Lachaux B., Sontag H., et al. [Pharmaco-epidemiological study on antipsychotic drug prescription in French Psychiatry: patient characteristics, antipsychotic treatment, and care management for schizophrenia]. Encephale 28 2 (2002) 129-138 [French]
46. Centorrino F., Eakin M., Bahk W.M., et al. Inpatient antipsychotic drug use in 1998, 1993, and 1989. Am J Psychiatry 159 (2002) 1932-1935
47. Chee Y.K., Ungvari G.S., Kin C.H., et al. A survey of antipsychotic treatment for schizophrenia in Hong Kong. Chin Med J (Engl) 110 (1997) 792-796
48. Covell N.H., Jackson C.T., Evans A.C., et al. Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr Bull 28 (2002) 17-29
49. Frangou S., and Lewis M. Atypical antipsychotics in ordinary clinical practice: a pharmaco-epidemiologic survey in a south London service. Eur Psychiatry 15 3 (2000) 220-226
50. Leslie D.L., and Rosenheck R.A. Use of pharmacy data to assess quality of pharmacotherapy for schizophrenia in a national health care system: individual and facility predictors. Med Care 39 9 (2001) 923-933
51. Procyshyn R.M., Kennedy N.B., Tse G., et al. Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry 46 4 (2001) 334-339
52. Wang P.S., West J.C., Tanielian T., et al. Recent patterns and predictors of antipsychotic medication regimens used to treat schizophrenia and other psychotic disorders. Schizophr Bull 26 2 (2000) 451-457
53. Weissman E.M. Antipsychotic prescribing practices in the Veterans Healthcare Administration-New York metropolitan region. Schizophr Bull 28 1 (2002) 31-42
54. Clark R.E., Bartels S.J., Mellman T.A., et al. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 28 1 (2002) 75-84
55. Johnson D.A.W., and Wright N.F. Drug prescribing for schizophrenic outpatients on depot injections: repeat surveys over 18 years. Br J Psychiatry 156 (1990) 827-834
56. Taylor D., Holmes R., Hilton T., et al. Evaluating and improving the quality of risperidone prescribing. Psychiatr Bull R Coll Psychiatr 22 (1997) 680-683
57. Patrick V., Levin E., and Schleifer S. Antipsychotic polypharmacy: is there evidence for its use?. J Psychiatr Pract 11 (2005) 248-257
58. Josiassen R.C., Joseph A., Kohegyi E., et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 162 (2005) 130-136
59. Friedman J., Ault K., and Powchik P. Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine. Biol Psychiatry 42 6 (1997) 522-523
60. Gupta S., Sonnenberg S.J., and Frank B. Olanzapine augmentation of clozapine. Ann Clin Psychiatry 10 3 (1998) 113-115
61. Henderson D.C., and Goff D.C. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J Clin Psychiatry 57 9 (1996) 395-397
62. Morera A.L., Barreiro P., and Cano-Munoz J.L. Risperidone and clozapine combination for the treatment of refractory schizophrenia. Acta Psychiatr Scand 99 4 (1999) 305-306 [discussion: 306-7]
63. Mowerman S., and Siris S.G. Adjunctive loxapine in a clozapine-resistant cohort of schizophrenic patients. Ann Clin Psychiatry 8 4 (1996) 193-197
64. Raskin S., Katz G., Zislin Z., et al. Clozapine and risperidone: combination/augmentation treatment of refractory schizophrenia: a preliminary observation. Acta Psychiatr Scand 101 4 (2000) 334-336
65. Bacher N.M., and Kaup B.A. Combining risperidone with standard neuroleptics for refractory schizophrenic patients. Am J Psychiatry 153 1 (1996) 137
66. Goss J.B. Concomitant use of thioridazine with risperidone. Am J Health Syst Pharm 52 9 (1995) 1012
67. Waring E.W., Devin P.G., and Dewan V. Treatment of schizophrenia with antipsychotics in combination. Can J Psychiatry 44 2 (1999) 189-190
68. Suzuki T., Uchida H., Tanaka K.F., et al. Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia. Int J Neuropsychopharmacol 7 (2004) 133-142
69. Shiloh R., Zemishlany Z., Aizenberg D., et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry 171 (1997) 569-573
70. Anil Yagcioglu A.E., Kivircik Akdede B.B., Turgut T.I., et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 66 1 (2005) 63-72
71. Honer W.G., Thornton A.E., Chen E.Y., et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 354 5 (2006) 472-482
72. Knight R.G., and Harrison A. A double-blind comparison of thiothixene and trifluoperazine/chlorpromazine composite in the treatment of schizophrenia. N Z Med J 89 (1979) 302-304
73. Citrome L., Jaffe A., Levine J., et al. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv 55 9 (2004) 1006-1013
74. Centorrino F., Goren J.L., Hennen J., et al. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry 161 (2004) 700-706
75. Chakos M.H., Glick I.D., Miller A.L., et al. Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv 57 8 (2006) 1094-1101
76. Williams C.L., Johnstone B.M., Keterson J.G., et al. Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia. Med Care 37 4 (1999) AS81-AS86
77. McCue R.E., Waheed R., and Urcuyo L. Polypharmacy in patients with schizophrenia. J Clin Psychiatry 64 9 (2003) 984-989
78. Edlinger M., Hausmann A., Kemmler G., et al. Trends in the pharmacological treatment of patients with schizophrenia over a 12 year observation period. Schizophr Res 77 (2005) 25-34
79. Siris S.G. Akinesia and postpsychotic depression: a difficult differential diagnosis. J Clin Psychiatry 48 (1987) 240-243
80. Siris S.G., Bermanzohn P.C., Mason S.E., et al. Maintenance imipramine therapy for secondary depression in schizophrenia: a controlled trial. Arch Gen Psychiatry 51 (1994) 109-115
81. Kirli S., and Caliskan M. A comparative study of sertraline versus imipramine in postpsychotic depressive disorder of schizophrenia. Schizophr Res 33 (1998) 103-111
82. Addington D., Addington J., Patten S., et al. Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia. J Clin Psychopharmacol 22 (2002) 20-25
83. Kasckow J.W., Mohamed S., Thallasinos A., et al. Citalopram augmentation of antipsychotic treatment in older schizophrenia patients. Int J Geriatr Psychiatry 16 (2001) 1163-1167
84. Glick I.D., Pham D., and Davis J.M. Concomitant medications may not improve outcome of antipsychotic monotherapy for stabilized patients with nonacute schizophrenia. J Clin Psychiatry 67 8 (2006) 1261-1265
85. Buchanan R.W., Kreyenbuhl J., Zito J.M., et al. The schizophrenia PORT pharmacological treatment recommendations: conformance and implications for symptoms and functional outcome. Schizophr Bull 28 1 (2002) 63-73
86. West J.C., Wilk J.E., Olfson M., et al. Patterns and quality of treatment for patients with schizophrenia in routine psychiatric practice. Psychiatr Serv 56 3 (2005) 283-291
87. Leslie D.L., and Rosenheck R.A. Adherence of schizophrenia pharmacotherapy to published treatment recommendations: patient, facility, and provider predictors. Schizophr Bull 30 3 (2004) 649-658
88. Dickey B., Normand S.L.T., Eisen S., et al. Associations between adherence to guidelines for antipsychotic dose and health status, side effects, and patient care experiences. Med Care 44 (2006) 827-834
89. Risperdal [package insert]. Available at: http://www.risperdal.com/active/janus/en_US/assets/common/company/pi/ris perdal.pdf. Accessed December 18, 2006.
90. McEvoy J.P., Hogarty G.E., and Steingard S. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 48 8 (1991) 739-745
91. Rifkin A., Doddi S., Karajgi B., et al. Dosage of haloperidol for schizophrenia. Arch Gen Psychiatry 48 2 (1991) 166-170
92. Tauscher J., and Kapur S. Choosing the right dose of antipsychotics in schizophrenia: lessons from neuroimaging studies. CNS Drugs 15 9 (2001) 671-678
93. Jones P.B., Barnes T.R.E., Davies L., et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry 63 10 (2006) 1079-1087
94. Stroup T.S., Lieberman J.A., McEvoy J.P., et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 163 4 (2006) 611-622
95. Essock S.M., Covell N.H., Davis S.M., et al. Effectiveness of switching antipsychotic medications. Am J Psychiatry 163 (2006) 2090-2095
96. Lacro J.P., Dunn L.B., Dolder C.R., et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 63 (2002) 892-909
97. Kane J.M. Review of treatments that can ameliorate nonadherence in patients with schizophrenia. J Clin Psychiatry 67 Suppl 5 (2006) 9-14
98. Leucht S., and Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry 67 Suppl 5 (2006) 3-8
99. Dolder C.R., Lacro J.P., Leckband S., et al. Interventions to improve antipsychotic medication adherence: review of recent literature. J Clin Psychopharmacol 23 (2003) 389-399
100. Velligan D.I., Lam Y.W.F., Glahn D.C., et al. Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull 32 (2006) 724-742